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Abstract 
 
Introduction: Current methods of identifying axillary node metastases in breast cancer patients are 
highly accurate, but are associated with several adverse events. This review evaluates the diagnostic 
accuracy of Magnetic Resonance Imaging techniques for identification of axillary metastases in early 
stage newly diagnosed breast cancer patients. 
 
Methods: Comprehensive searches were conducted in April 2009. Study quality was assessed. 
Sensitivity and specificity were meta-analysed using a bivariate random effects approach, utilising 
pathological diagnosis via node biopsy as the comparative gold standard. 
 
Results: Based on the highest sensitivity and specificity reported in each of the nine studies 
evaluating MRI (n=307 patients), mean sensitivity was 90% (95% CI: 78-96%; range 65-100%) and 
mean specificity 90% (95% CI: 75-96%; range 54-100%). Across five studies evaluating ultrasmall 
super-paramagnetic iron oxide (USPIO)-enhanced MRI (n=93), mean sensitivity was 98% (95% CI: 
61-100%) and mean specificity 96% (95% CI: 72-100%). Across three studies of gadolinium-
enhanced MRI (n=187), mean sensitivity was 88% (95% CI: 78-94%) and mean specificity 73% (95% 
CI: 63-81%). In the single study of in vivo proton MR spectroscopy (n=27), sensitivity was 65% 
(95% CI: 38-86%) and specificity 100% (95% CI: 69-100%).  
 
Conclusions: USPIO-enhanced MRI showed a trend towards higher sensitivity and specificity and 
may make a useful addition to the current diagnostic pathway. Additional larger studies with 
standardised methods and standardised criteria for classifying a node as positive are needed. Current 
estimates of sensitivity and specificity do not support replacement of SLNB with any current MRI 
technology in this patient group.  
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Introduction 
 
Identification of axillary metastases in early stage newly diagnosed breast cancer is important for 
staging disease and planning treatment, but current techniques are associated with a number of 
adverse events. Approximately 40% of women who present with early stage breast cancer also have 
axillary metastases. The number of metastases present determines the stage of the disease, contributes 
to the overall prognosis and helps in the planning of adjuvant treatment. In the UK, women usually 
follow the diagnostic pathway described in the National Institute for Health and Clinical Excellence 
(NICE)  guidelines(1) (Figure 1). If women have a negative ultrasound or ultrasound-guided biopsy of 
the axilla, they proceed to sentinel lymph node biopsy. Sentinel lymph node biopsy (SLNB) is the 
excision of the first nodes to receive lymph from the breast (the sentinel nodes). Once removed, the 
lymph nodes are subject to histological analysis to determine the presence of metastases. If SLNB or 
the ultrasound-guided biopsy are positive, women proceed to axillary lymph node dissection (ALND), 
where all lymph nodes are removed to reduce the risk of uncontrolled axillary disease.  
 
SLNB is a highly accurate method of identifying axillary metastases, and whilst it involves the 
removal of fewer lymph nodes than ALND, it is still associated with both short and long term adverse 
events. It is estimated that lymphoedema occurs in 21%(2-4)  of patients who undergo ALND and 
7%(5) of patients who undergo SLNB. Other adverse events include surgical complications such as 
risk of infection, seroma, insertion of surgical drains and sensitivity to the dyes used in SLNB. Non-
invasive alternatives to these diagnostic tests could reduce the incidence of adverse events in women 
undergoing staging procedures. Any such technique would need to demonstrate acceptable sensitivity 
to avoid missing metastatic nodes and acceptable specificity to avoid false positive diagnoses, as well 
as acceptable levels of adverse events.  
 
Magnetic resonance imaging (MRI) is a non-ionising, minimally-invasive  in-vivo imaging technique. 
Unlike x-ray computerised tomography (CT), which uses the attenuation of ionising radiation as the 
basis of image contrast, standard MRI relies on the magnetic resonance characteristics of hydrogen 
nuclei (predominantly associated with water and fat) within the body. The technique utilises how 
these nuclei respond when placed in a magnetic field and are ‘excited’ by radio-waves during the 
application or switching of magnetic field gradients. The resultant signal is used to build up a set of 
images in 2 or 3 dimensions and, of particular importance, the contrast between different soft-tissues 
and pathologies can be highly informative, depending on many factors such as the hydrogen nuclei’s 
chemical environment. Of importance to axilla imaging, MRI can thus provide information about the 
size and morphology of lymph nodes. The administration of intravenous contrast media can give 
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additional information. The presence of exogenous paramagnetic contrast media perturbs the 
magnetic field at localities where the media collects, which leads to alterations of local image 
contrast. This can increase lesion conspicuity (where the media collects) and provide additional 
information regarding the nature of pathological tissue based on the pattern of uptake. Such 
information can aid the judgement of whether a node is metastatic or not. As well as MRI of hydrogen 
nuclei attached to water and fat, the technique of proton MR spectroscopy (1H-MRS) can provide 
information regarding other molecules, the chemical status of which may be relevant to the presence 
of pathology.  To consider MR imaging and spectroscopy as an alternative to SLNB, its sensitivity 
and specificity must be estimated. We have conducted a systematic review and meta-analysis to 
evaluate the diagnostic accuracy and adverse events associated with MRI for assessment of axillary 
metastases in early stage newly diagnosed breast cancer patients.  
 
[Figure 1.] 
 
Methods 
 
Search strategy 
The systematic review followed the principles recommended in the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA)(6;7) statement. Eleven databases were searched 
in April 2009, namely MEDLINE, Medline in Process, EMBASE, CINAHL, Cochrane Database of 
Systematic Reviews, Cochrane CENTRAL Register of Controlled Trials, DARE, NHS EED, HTA 
database, Science Citation Index, and BIOSIS previews. The search strategy included terms for breast 
cancer, MRI imaging, the axilla or lymph nodes, and diagnostic studies. Searches were also made of 
the following research registers: National Research Register archive until 2007(www.nrr.nhs.uk), UK 
NIHR Clinical Research Network post-2007 (www.ukcrn.org.uk), ClinicalTrials.gov 
(www.clinicaltrials.gov) and Current Controlled Trials (www.controlled-trials.com), and the 
following relevant conference proceedings: American Society of Clinical Oncology (ASCO) and 
European Society for Medical Oncology (ESMO).  Additional searching included contact with experts 
and scrutiny of bibliographies of retrieved papers and reviews. The search was undertaken as part of a 
broader review on imaging of the axilla for the UK NIHR Health Technology Assessment (HTA) 
Programme.(8) An additional brief search was performed on MEDLINE for new literature between 
2009 to January 2011. Searches were not restricted according to language or publication date. 
 
Study selection strategy 
Studies were selected for inclusion by two reviewers (SH and KC) in three stages. Irrelevant titles 
were excluded by one reviewer and checked by a second. Abstracts of the remaining titles were 
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assessed for inclusion by two reviewers, and the full text of potentially includable articles were 
obtained and scrutinised for inclusion by two reviewers.  
 
Inclusion and exclusion criteria 
Cohort studies were included if they assessed the diagnostic accuracy of any MRI technique for 
assessing axillary metastases in women with early stage newly diagnosed breast cancer, defined as  
TNM stage I, II or IIIA.(9-11) Patients with carcinoma in situ (ductal or lobular; DCIS or LCIS) were 
excluded where possible as they do not generally undergo diagnostic axillary surgery. Studies were 
only included if 80% of patients met the above criteria, or if data could be extracted for a subset of 
patients where 80% met the above criteria. Studies were included if they compared MRI to an 
acceptable reference standards test, defined as ALND, SLNB or 4NS. Only studies in which numbers 
of true negative (TN), true positive (TP), false negative (FN) and false positive (FP) cases were 
reported or could be calculated were included. Non-English language studies and case-control studies 
were excluded, though the searches did not identify any case-control studies. 
 
Data extraction and quality assessment 
Data was extracted from included studies by one reviewer and checked by a second. Studies were 
quality assessed by two reviewers using the QUality Assessment of Diagnostic Accuracy 
Studies (QUADAS) checklist.(12) In accordance with the guidelines for using QUADAS, two 
items from the published checklist were omitted as they were not relevant to this review (partial 
verification bias, incorporation bias). The “description of selection criteria” item was also omitted as 
this was covered by the “patient spectrum” item, where only studies which recruited early-stage 
newly-diagnosed patients in a prospective, consecutive manner scored positively. The remaining ten 
items were used to assess study quality. 
 
Data synthesis 
A pooled analysis of results was undertaken where study homogeneity allowed. As sensitivity and 
specificity are inversely linked, a bivariate random effects method was employed, using Stata 
(copyright StataCorp). This approach assumes a bivariate normal distribution for the logits of 
sensitivity and specificity, which allows the correlation between them to be accounted for in the meta-
regression model; covariates may be used to adjust the (marginal) logits of both sensitivity and 
specificity.(13;14) Where significant heterogeneity was observed, the random effects method was 
used in order to account for variation both within and between studies. To explore possible sources of 
bias, all study quality variables were added as covariates in univariate regression models for 
sensitivity and specificity to test whether any variables had a significant effect (p < 0.10) on 
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sensitivity or specificity. Review Manager 5 (copyright Cochrane Collaboration) (15)was used to 
generate graphical representations. 
 
 
Results 
 
Number and characteristics of included studies 
Searches identified 658 unique titles for the broader review relating to imaging of the axilla. The full 
text of 138 titles were obtained and examined for inclusion in the broad review. Of these, nine 
titles(16-24) representing nine studies met the inclusion criteria for this review, and were included. 
Three studies(18;21;22) reported results for gadolinium enhanced MRI, five(16;17;19;20;23) for 
ultrasmall super paramagnetic iron oxide (USPIO)-enhanced MRI and one(24) for 1H-MRS.  
 
Study and patient characteristics are reported in Table 1. Where reported, mean age of included 
participants ranged from 53 to 66. Study size ranged from 10 to 67 patients, though one study only 
reported the number of axillae (75 axillae). Of the included studies six were prospective, and five of 
these also stated that consecutive patients were selected. The reference standard was ALND in eight 
studies, and ALND or SLNB in the other study.  
 
[Insert table 1.] 
 
Quality of included studies 
Study quality was generally acceptable (Figure 2) with most items scoring positively. Four items 
scored poorly or unclear overall: representative patient spectrum, blinding of reference standard to 
index test results, availability of relevant clinical information and reporting of uninterpretable results. 
 
[insert figure2] 
 
Sensitivity and Specificity of MRI 
Across all studies included, sensitivity of MRI ranged from 65%(24) to 100%(16;17;19;22;23) and 
specificity ranged from 54%(22) to 100%(17;19;20;24)  (Figure 3). Several studies used more than 
one set of criteria for scoring a node as positive, such as size, morphology, contrast uptake or 
combinations of these. When pooling the data, results for the criteria that gave the best estimates of 
diagnostic accuracy per study were used. The pooled estimates of sensitivity and specificity were 90% 
(95% confidence interval (CI) 78% to 96%) and 90% (95% CI 75% to 96%) respectively (Table 2). 
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[Insert figure 3] 
 
 
[Insert Table 2.] 
 
 
When each MRI modality is considered separately and the estimates of sensitivity and specificity are 
pooled, USPIO-enhanced MRI gives the highest estimates with a pooled sensitivity of 98% and 
specificity of 96% (Table 2). These figures are similar to published estimates of sensitivity and 
specificity of SLNB (sensitivity of approximately 93-95%, and specificity of 100%,(25;26))when 
compared to ALND and are therefore clinically promising. However, it should be noted that the 
number of patients is small at 93.  Gadolinium-enhanced MRI gave somewhat poorer estimates of 
88% and 73% respectively (Table 2), whilst MR spectroscopy estimates are based on one study only, 
and had sensitivity 65% and specificity 100%.  
 
Subgroup analyses: criteria for positivity 
As criteria for positivity varied within and across studies of USPIO enhanced and gadolinium-
enhanced MRI, subgroup analyses were performed to assess the effects of these criteria on sensitivity 
and specificity. Within this analysis, some studies appear more than once. The exact combinations of 
criteria were often not consistent across studies and the methods of interpreting contrast uptake 
patterns varied within and between studies. 
 
The most promising diagnostic accuracy in subgroup analyses comes from a pooling of four studies 
which used USPIO uptake pattern as a criterion for positivity (Table 2). The studies which assessed 
gadolinium-enhanced MRI used different combinations of criteria for positivity, including uptake 
pattern, dynamic signal intensity, size, morphology and washout pattern (Table 2).  These yielded 
pairs of estimates lower than those for USPIO-enhanced MRI. Size and morphological criteria for 
positivity were also considered across the two MRI modalities, though these analyses were mostly 
based on one study in each category, and none yielded estimates superior to the uptake pattern of 
USPIO-enhanced MRI. 
 
 
Sensitivity analyses 
Analyses were attempted to assess the effects of study characteristics and study quality on estimates 
of sensitivity and specificity. Analyses of the effects of size and number of axillary metastases, 
clinical nodal status, T-stage and reference standard used were not possible due to lack of data or lack 
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of variation in data between studies. Studies in which all analysed patients were early-stage newly-
diagnosed and did not have a diagnosis of DCIS had a trend towards a higher sensitivity, and a 
significantly lower specificity, than studies in which not all patients were early-stage, newly-
diagnosed and non-DCIS; however, there was wide variation in results between studies. There was no 
clear correlation between prevalence of axillary metastases within the study and estimates of 
sensitivity and specificity. There was also no clear correlation between any of the quality assessment 
items and estimates of diagnostic accuracy, but this analysis is limited by a lack of variation in quality 
assessment scores between studies.  
 
Withdrawal rates and adverse events 
Four studies reported that between 3% and 18% of patients withdrew. Reasons for withdrawal 
included no ALND, inadequate MRI data, and claustrophobia or poor health. No serious adverse 
effects were reported in any of the MRI studies. Mild-to-moderate adverse effects included mild rash 
following USPIO administration (recovered without treatment or following antihistamine treatment) 
and inability to complete the MRI scan due to claustrophobia or back pain as a result of holding the 
same position for some time. In addition, many of the studies excluded patients with contraindications 
to MRI, such as strong allergic disposition, allergy to contrast agents, or liver dysfunction. 
 
 
 
Discussion 
 
Overall pooled estimates of sensitivity and specificity for MRI were 90% and 90% respectively, with 
USPIO-enhanced MRI giving the highest overall diagnostic accuracy with sensitivity of 98% and 
specificity of 96%. Gadolinium-enhanced MRI gave sensitivity of 88% and specificity of 73% and 
MR spectroscopy gave a sensitivity of 65% and specificity of 100%. Confidence intervals were wide, 
and there was considerable variation in the criteria used to class a node as positive. 
 
This study uses a bivariate random effects method of meta-analysis to pool estimates of sensitivity 
and specificity, which takes into account the inverse relationship between the two values. We have 
also made a thorough review of the literature to April 2009, and the brief update search performed in 
MEDLINE in January 2011 indicates that no eligible studies have been published subsequently. 
However, the study is limited by the small amount of available data, both in terms of numbers of 
participants and numbers of studies.  
 
SLNB is reported to have a sensitivity of approximately 93-95%, and a specificity of 100%.(25;26) 
Replacing SLNB at a population level with MRI, based on the overall pooled estimates within this 
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review (pooled sensitivity 90%, specificity 90%), would result in an increase in missed metastases as 
MRI has a lower sensitivity than SLNB, leading to more false negative cases. It would result in an 
increase in unnecessary ALND procedures, as MRI has lower specificity than SLNB, leading to more 
false positive cases. It would also mean a large number of women would not undergo SLNB and 
would therefore avoid the risk of adverse events associated with these procedures. However, the 
associated increase in women with false negative results who would therefore be put at greater risk of 
cancer recurrence may not be acceptable despite the reduction in adverse events.  
 
Subgroup analyses indicated, however, that USPIO-enhanced MRI had superior sensitivity (98%), but 
inferior specificity (96%) to SLNB. In addition, subgroup analyses indicate that the criteria used to 
classify a node as positive may affect diagnostic accuracy, though wide confidence intervals preclude 
firm conclusions. Whilst these results come from a small number of patients and the criteria for 
positivity varied between the studies that have been pooled, they are promising and fall within the 
ranges of sensitivity reported for SLNB. Further technological development, especially of USPIO-
enhanced MRI, would seem warranted, and research to identify the optimal criteria for classing a node 
as positive may lead to improvements in diagnostic accuracy independent of technological advances.  
 
Given current estimates of diagnostic accuracy, an alternative strategy, where MRI is added to the 
current pathway before ALND/SLNB, could be considered. This way, women at greatest risk 
(positive for nodal metastases by any of ultrasound, biopsy or USPIO-enhanced MRI) could be 
triaged for ALND, whilst those who are negative would still receive SLNB and benefit from the high 
specificity of this procedure. Fewer women would have to undergo two operations, namely SLNB 
followed by ALND where positive. A cost-effectiveness model considering these two options and 
based on the results of this review, is reported elsewhere.(8;27) 
 
An alternative technique, the intra-operative analysis of lymph nodes, is in use in some centres. This 
technique aims to reduce the need for women to undergo two operations as excised nodes are tested 
for metastases during the initial operation to remove the tumour. Improvements in and more 
widespread use of this technique may reduce the potential usefulness of adding MRI to the diagnostic 
pathway prior to ALND/SLNB.  
 
 
Conclusion 
 
In summary, USPIO-enhanced MRI shows promising diagnostic accuracy for identifying axillary 
lymph node metastases in patients with early stage newly diagnosed breast cancer. Furthermore, MRI 
may make a useful addition to the current diagnostic pathway, by enabling more women to be 
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correctly triaged for ALND, and avoid the need for two operations. However, there is a need for more 
and larger studies with standardised methods and standardised criteria for classifying a node as 
positive before any changes to policy and practice should be considered. Current estimates of 
sensitivity and specificity do not support replacement of SLNB with the assessed current MRI 
methodologies and technologies.  
 
 
This project was funded by the NIHR Health Technology Assessment Programme (project number 
08/35/01) and will be published in full in the monograph series Health Technology Assessment. See 
the HTA programme website for further project information. The views and opinions expressed 
therein are those of the authors and do not necessarily reflect those of the Department of Health. 
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Figure 1: Diagnostic pathway for axillary metastases as recommended in NICE 2009 breast 
cancer guidelines (1) 
 
 
 
*Either fine needle aspiration cytology (FNAC) or core biopsy. 
 
 
Figure 2. Quality of included studies scored against the QUADAS criteria. 
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Figure 3.  Forest plot of all MRI studies* 
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Specificity
0 0.2 0.4 0.6 0.8 1
Dynamic gadolinium-enhanced MRI
Study
Murray 2002
Kvistad 2000
TP
10
20
FP
17
4
FN
0
4
TN
20
37
MRI criteria
Dynamic Gd + >4sq-mm
Dynamic Gd
Sensitivity
1.00 [0.69, 1.00]
0.83 [0.63, 0.95]
Specificity
0.54 [0.37, 0.71]
0.90 [0.77, 0.97]
Sensitivity
0 0.2 0.4 0.6 0.8 1
Specificity
0 0.2 0.4 0.6 0.8 1
MR spectroscopy (in vivo)
Study
Yeung 2002
TP
11
FP
0
FN
6
TN
10
MRI criteria
MR spectroscopy (in vivo)
Sensitivity
0.65 [0.38, 0.86]
Specificity
1.00 [0.69, 1.00]
Sensitivity
0 0.2 0.4 0.6 0.8 1
Specificity
0 0.2 0.4 0.6 0.8 1
 
TP=true positive, FP=false positive, FN=false negative, TN=true negative. Brackets show 95% confidence intervals. The 
figure shows the sensitivity and specificity for each study (squares) and 95% confidence intervals (horizontal lines). *Where 
studies report results using more than one set of criteria for positivity, these analyses use data corresponding to the criteria 
with the highest reported estimates of diagnostic accuracy per study. The criteria used for each study are shown on the plot. 
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Table 1.  Characteristics of included MRI studies 
 
Study Country Index test Reference 
standard 
Prospective/ 
retrospective? 
Consecutive? 
N met 
criteria† 
N analysed 
Age 
Gender 
Cancer stage Clinical nodal 
status 
Prevalence 
of axillary 
metastases 
Confirmation 
of breast 
cancer 
Other inclusion and exclu
criteria 
Kimura 
2009(17) 
Japan USPIO-
enhanced 
ALND and/or 
SLNB 
Prospective 
Consecutive 
10 
10 
66 (35 to 79) 
Female 
100% clinically T2 N0 
M0 (stage IIA) 
100% negative 20% Pathology (no 
further detail) 
Exclusion: strong allergic 
disposition, liver dysfuncti
Harada 
2007(16) 
Japan USPIO-
enhanced 
100% ALND Prospective 
Consecutive 
33 
33 
58 (36-77) 
97% female 
Stage II=73% 
Stage IIIA=24% 
Stage IIIB=3% 
NR 70% Pathology (no 
further detail) 
Exclusion: stage I, strong a
disposition, liver dysfuncti
Memarsadeghi 
2006(19) 
Austria USPIO-
enhanced 
100% ALND Prospective 
Consecutive 
24 
22 
60 (40-79) 
Female 
T1=59%, T2=41% NR 27% CNB Exclusion: contraindicatio
MRI, allergy to dextran or
salts, chemotherapy or 
radiotherapy, no ALND, 
pregnancy, lactation, unab
cooperate, other trial, unde
of guardian 
Stadnik 
2006(23) 
Belgium USPIO-
enhanced 
100% ALND Prospective 
NR 
10 
10 
56 (41 to 74) 
Female 
Stage not reported.§ 
Included pts scheduled 
for mastectomy 
NR 50% NR Exclusion: not scheduled f
mastectomy, contraindicat
MRI, strong allergic dispo
to gadolinium, dextrans or
salts, unable to obtain PET
technical or accessibility r
Michel 
2002(20) 
Switzerla
nd 
USPIO-
enhanced 
100% ALND Prospective 
Consecutive 
18 
18 
53 (22-76) 
Female 
T1=56%, T2=39%, 
T4=6% 
NR 61% Cytology 95%, 
histology 5% 
Exclusion: strong allergic 
disposition, contraindicatio
MRI 
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Study Country Index test Reference 
standard 
Prospective/ 
retrospective? 
Consecutive? 
N met 
criteria† 
N analysed 
Age 
Gender 
Cancer stage Clinical nodal 
status 
Prevalence 
of axillary 
metastases 
Confirmation 
of breast 
cancer 
Other inclusion and exclu
criteria 
Murray 
2002(22) 
UK Dynamic 
gadolinium-
enhanced 
100% ALND NR 
NR 
47 
47 
63 (50-87) 
Female 
T1/T2=100% NR 21% Histology (no 
further detail) 
Exclusion: primary tumou
<0.5cm or >3.1cm. 
Kvistad 
2000(18) 
Norway Dynamic 
gadolinium-
enhanced 
100% ALND NR 
NR 
67 
65 
59 (38-79) 
NR 
T1=58%, T2=31%, 
T3/T4=11% (neoadj 
chemotherapy) 
Positive and 
negative (% 
NR) 
37% Histology or 
FNAC 
NR 
Mumtaz 
1997(21) 
UK Gadolinium-
enhanced 
100% ALND NR 
NR 
92 axilla 
75 axilla 
49‡ (29-80) 
NR 
T1=11%, T2=72%, 
T3=3%, T4=3%, 
Tx=11%, DCIS=4% 
NR 53% FNAC 90%, 
CNB 10% (if 
equivocal) 
NR 
Yeung 
2002(24) 
Hong 
Kong 
MR 
spectroscopy 
100% ALND Prospective 
Consecutive 
32 
27 
53 (26-82) 
NR 
Stage not reported∫ 52% negative  
48% positive 
63% CNB Exclusion: receiving 
chemotherapy 
†Number meeting criteria for this review. § Stage was not reported, but tumours were 1-3cm indicating all participants were early stage. ∫ Stage was not reported, but only data relating to patients with 
tumours ≤5cm (early stage) were used in analysis.  Ages are mean (range) unless marked ‡which indicates median (range). ALND=axillary lymph node dissection; CNB=core needle biopsy; 
FNAC=fine needle aspiration cytology; MRI=magnetic resonance imaging; NR=not reported; SLNB=sentinel lymph node biopsy; USPIO= ultrasmall super-paramagnetic iron oxide. 
 
 
Table 2. Summary of pooled sensitivities and specificities for MRI studies* overall and according to criteria for positivity. 
 
Diagnostic test N studies N patients Sensitivity (%) (95% CI) Specificity (%) (95% CI) 
All MRI studies 
All MRI studies 9 307 90 (78 to 96) 90 (75 to 96) 
MRI studies by type of MRI 
USPIO-enhanced MRI 5 93 98 (61 to 100) 96 (72 to 100) 
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Diagnostic test N studies N patients Sensitivity (%) (95% CI) Specificity (%) (95% CI) 
Gadolinium-enhanced MRI 3 187 88 (78 to 94) 73 (63 to 81) 
MR spectroscopy 1 27 65 (38 to 86) 100 (69 to 100) 
Criteria for positivity N studies N patients Sensitivity (%) (95% CI) Specificity (%) (95% CI) 
USPIO-based criteria 
USPIO uptake 4 75 98 (63 to 100) 94 (69 to 99) 
USPIO uptake, size >10mm, round shape (not clear if "and" or "or") 1 18 82 (48 to 98) 100 (59 to 100) 
Gadolinium-based criteria 
Gd uptake, size >5mm(21) (not clear if "and" or "or") 1 75 90 (76 to 97) 83 (66 to 93) 
Dynamic Gd signal intensity increase 2 112 86 (68 to 94) 59 (45 to 72) 
Dynamic Gd + positive washout 1 65 71 (49 to 87) 90 (77 to 97) 
Dynamic Gd + size >4sq-mm 1 47 100 (69 to 100) 54 (37 to 71) 
Dynamic Gd + size >5mm + abnormal morphology 1 65 63 (41 to 81) 93 (80 to 98) 
Size and/or morphological criteria 
Size >4sq-mm 1 47 100 (69 to 100) 19 (08 to 35) 
Size >5mm 1 33 100 (85 to 100) 10 (0 to 45) 
Size >10mm 1 33 43 (23 to 66) 80 (44 to 97) 
Abnormal morphology 1 33 96 (78 to 100) 20 (03 to 56) 
Size >5m + abnormal morphology 1 65 63 (41 to 81) 80 (65 to 91) 
Size >10mm and/or round shape 1 22 83 (36 to 100) 31 (11 to 59) 
*Where studies report results using more than one set of criteria for positivity, these analyses use data corresponding to the criteria with the highest reported estimates of diagnostic accuracy per 
study. Gd = Gadolinium 
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